CR
CRDL.US Cardiol Therapeutics Inc Class A
- Market cap
- USD 122M
- P/E
- -
- P/B
- 7.46x
- ROE
- -156.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRDL.US undervalued?
Graham numberThe Graham number of Cardiol Therapeutics Inc Class A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardiol Therapeutics Inc Class A fundamental analysis
No fundamental analysis for Cardiol Therapeutics Inc Class A yet.
Cardiol Therapeutics Inc Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38,…
Full company profileCardiol Therapeutics Inc Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cardiol Therapeutics Inc Class A annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 78.8K | 62.3K | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -53.3K | -91.5K | -116K | -180K | -112K | -162K | -187K | - | - | - |
| Operating Income | -1.59M | -7.39M | -10.9M | -16.2M | -30.6M | -30.5M | -22.5M | -40.3M | -34.3M | -40.7M |
| EBITDA | -1.50M | -7.30M | -10.4M | -16.0M | -24.8M | -22.6M | -21.0M | -36.3M | -33.7M | -39.0M |
| Net Income | -1.66M | -15.9M | -10.6M | -16.2M | -25.0M | -22.8M | -21.2M | -36.7M | -33.8M | -43.3M |
| EPS | -0.07 | -0.66 | -0.41 | -0.54 | -0.58 | -0.37 | -0.33 | -0.51 | -0.39 | -0.37 |
| Balance Sheet | ||||||||||
| Total Assets | 3.22M | 24.7M | 15.5M | 15.9M | 87.9M | 45.8M | 36.7M | 31.9M | 23.6M | 33.0M |
| Total Liabilities | 367K | 2.41M | 831K | 2.62M | 11.6M | 7.25M | 8.45M | 7.14M | 5.74M | 5.30M |
| Shareholders' Equity | 2.85M | 22.3M | 14.7M | 13.3M | 76.2M | 38.5M | 28.2M | 24.7M | 17.9M | 27.7M |
| Cash & Short-term Investments | 2.36M | 16.7M | 6.96M | 14.0M | 83.9M | 43.9M | 34.9M | 30.6M | 21.4M | 29.3M |
| Total Debt | 190K | 269K | 191K | 157K | 118K | 53.8K | 174K | 159K | 126K | 97.6K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.29M | -10.9M | -11.4M | -9.13M | -23.6M | -27.2M | -25.2M | -25.1M | -23.9M | -21.8M |
| Capital Expenditure | 29.2K | 13.8K | 424K | 40.6K | 12.9K | 74.7K | 64.3K | 21.3K | 24.5K | 99.6K |
| Free Cash Flow | -1.32M | -10.9M | -11.8M | -9.17M | -23.6M | -27.3M | -25.2M | -25.1M | -23.9M | -21.9M |
| Ratios | ||||||||||
| ROE | -58.2% | -71.4% | -71.9% | -122.1% | -32.8% | -59.3% | -75.1% | -148.3% | -189.2% | -156.3% |
| ROA | -51.6% | -64.4% | -68.1% | -101.9% | -28.5% | -49.9% | -57.8% | -115.1% | -143.2% | -131.2% |
| Net Profit Margin | - | - | - | -20,570.9% | -40,170.9% | - | - | - | - | - |
| Debt to Equity | 0.07x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cardiol Therapeutics Inc Class A dividends
Cardiol Therapeutics Inc Class A has not paid dividends in the last 9 fiscal years.
Who owns Cardiol Therapeutics Inc Class A
- Insiders 2.22%
- Institutions 26.91%
- Public & others 70.87%
- Shares outstanding 122M
- Free float 92.0M
Top funds holding CRDL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Global X Marijuana Life Sciences ETF | 880K | 0.72% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 101K | 0.08% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 18.5K | 0.02% | -69.56% | Aug 2026 |
Top institutions holding CRDL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mmcap International Inc. Spc | 15.6M | 12.84% | +1.60% | Jun 2026 |
| Tejara Capital Ltd | 5.11M | 4.21% | -0.32% | Jun 2026 |
| Ikarian Capital, LLC | 3.33M | 2.74% | +22.02% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 976K | 0.80% | +22.75% | Jun 2026 |
| Citadel Advisors Llc | 797K | 0.66% | -2.85% | Jun 2026 |
| Renaissance Technologies Corp | 773K | 0.64% | +236.30% | Jun 2026 |
| Two Sigma Investments LLC | 747K | 0.61% | +39.82% | Jun 2026 |
| INTEGRITY ALLIANCE, LLC. | 388K | 0.32% | -16.46% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 355K | 0.29% | +41.77% | Jun 2026 |
| The Goldman Sachs Group Inc | 334K | 0.27% | +0.45% | Jun 2026 |
| We Are One Seven, LLC | 100K | 0.08% | 0.00% | Jun 2026 |
| 1832 Asset Management L.P | 100K | 0.08% | 0.00% | Jun 2026 |
| Summit Financial LLC | 99.1K | 0.08% | -4.76% | Jun 2026 |
| Jane Street Group LLC | 53.4K | 0.04% | -57.93% | Jun 2026 |
| JPMorgan Chase & Co | 48.1K | 0.04% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 47.2K | 0.04% | 0.00% | Jun 2026 |
| Acadian Asset Management LLC | 44.3K | 0.04% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 42.2K | 0.03% | -19.53% | Jun 2026 |
| Marble Harbor Investment Counsel, LLC | 39.9K | 0.03% | 0.00% | Jun 2026 |
| Boyer Financial Services, Inc. | 34.1K | 0.03% | 0.00% | Sep 2026 |
Cardiol Therapeutics Inc Class A company profile
- Company name
- Cardiol Therapeutics Inc Class A
- Ticker
- CRDL.US
- ISIN
- CA14161Y2006
- Exchange
- USA Stocks
- Listed since
- Jan 15, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
- Phone
- 289 910 0850
- Website
- cardiolrx.com
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc Class A management
6- Mr. David G. Elsley MBAPresident, CEO & Director
- Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBACFO, Corporate Secretary & Director
- Mr. Bernard Lim B.Sc.Chief Operating Officer
- Dr. Andrew Warwick Hamer M.D.Chief Medical Officer and Head of Research & Development · born 1962
- Trevor BurnsInvestor Relations
- Mr. John A. Geddes BSCPT, MBAVice President of Corporate Development